Alnylam's ESC Data Show Vutrisiran Benefit Across ATTR-CM Settings, Zilebesiran BP Control
ALNY sits 21% above its 52-week low of $197.81.
Summary
Alnylam presented new analyses at ESC Congress 2026 reinforcing vutrisiran's consistent benefit in ATTR-CM regardless of background tafamidis use, with a 25% less decline in intrinsic capacity and fewer adverse events versus placebo. Pooled Phase 3 data across 1,402 patients showed consistent treatment effects between sexes. Zilebesiran subgroup data in patients on diuretics showed greater SBP reductions, supporting its Phase 3 ZENITH trial. These data strengthen the case for AMVUTTRA as a first-line ATTR-CM therapy and expand the potential of RNAi in hypertension. The company will host an RNAi Roundtable on zilebesiran on September 17, 2026.
At the time of this announcement, ALNY was trading at $240.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7B. The 52-week trading range was $197.81 to $495.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.